Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There was no significant difference in vitamin D levels between the two groups.Characteristics of the subjects according to MAFLDTotal subjects (n = 852)MAFLDp-valueAUROC (95% CI)No (n = 574)Yes (n = 278)Sex < 0.0001 Male300 (52.3)209 (75.2) Female274 (47.7)69 (24.8)Alcohol consumption0.147 N360 (62.7)160 (57.6) Y214 (37.3)118 (42.4)Smoking < 0.0001 N446 (77.7)184 (66.2) Y128 (22.3)94 (33.8)FLI < 0.0001 30 < 407 (89.8)80 (43.0) ≥ 6046 (10.2)106 (57.0)Age (years)52.44 ± 10.2052.97 ± 9.310.462BMI23.63 ± 2.8426.64 ± 3.12 < 0.0001SBP (mmHg)121.19 ± 12.59126.15 ± 11.77 < 0.0001DBP (mmHg)74.63 ± 9.5678.84 ± 10.02 < 0.0001WC (cm)82.34 ± 8.0789.23 ± 9.17 < 0.0001FBS (mg/dL)92.3 ± 23.3899.93 ± 26.27 < 0.0001TG (mg/dL)98.8 ± 64.16150.91 ± 143.04 < 0.0001HDL-C (mg/dL)56.74 ± 12.952.4 ± 13.72 < 0.0001LDL-C (mg/dL)119.53 ± 32.72124.16 ± 38.030.082AST (IU/L)30.82 ± 21.9437.66 ± 38.420.001ALT (IU/L)27.52 ± 24.3240.15 ± 29.71 < 0.00010.701 (0.657 to 0.745)GGT (IU/L)36.76 ± 66.8672.79 ± 215.350.0070.668 (0.622 to 0.714)Uric acid/creatinine6.29 ± 1.756.61 ± 1.560.011hs-CRP (mg/L)1.65 ± 3.932.03 ± 3.610.2160.620 (0.572 to 0.668)TC (mg/dL)199.95 ± 35.45205.11 ± 44.300.091WBC (103/µL)6019.63 ± 1735.576722.82 ± 1950.21 < 0.0001Hemoglobin (g/dL)14.23 ± 1.5015.34 ± 1.50 < 0.00010.682 (0.635 to 0.729)Insulin (µIU/mL)4.41 ± 3.027.76 ± 6.46 < 0.00010.717 (0.672 to 0.761)Vitamin D (ng/mL)18.99 ± 8.8919.27 ± 7.860.688Fatty liver index23.1 ± 20.7548.63 ± 25.5 < 0.00010.776 (0.737 to 0.816)Data are expressed as number (percentage) or mean ± standard deviation.
Source: General characteristics of patient with and those without MAFLD. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Medical records of men and women aged ≥ 19 years who underwent abdominal computed tomography (CT) examination at our facility between March 2012 and October 2019 were retrospectively reviewed.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Study design awaiting verification · Diabetology & Metabolic Syndrome · 2022
Original publication title
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature for nonalcoholic fatty liver. Along with obesity, fatty liver associated with metabolic dysfunction is increasing and has become a serious socioeconomic problem. Non-invasive testing for the confirmation of MAFLD, including the fatty liver index (FLI), can be used as an alternative method for diagnosing steatosis when imaging modalities are not available. To date, few studies have examined the effectiveness and validity of FLI for diagnosing MAFLD. Therefore, this study analyzed the effectiveness and validity of FLI for diagnosing MAFLD.
Source: AimsAbstract: What methods does the paper describe?
Medical records of men and women aged ≥ 19 years who underwent abdominal computed tomography (CT) examination at our facility between March 2012 and October 2019 were retrospectively reviewed. A comparative analysis between non-continuous variables was performed using the chi-squared test. The area under receiver operating characteristic (AUROC) curve was used to verify the effectiveness of FLI as a predictive index for MAFLD.
Source: MethodsAbstract: Results
Analysis of the association between MAFLD and abdominal CT revealed that the sensitivity and specificity of FLI for diagnosing MAFLD were 0.712 and 0.713, respectively. The AUROC of FLI for predicting MAFLD was 0.776.
Source: ResultsAbstract: Conclusions
Our study verified the accuracy of FLI for predicting MAFLD using CT. The FLI can be used as a simple and cost-effective tool for screening MAFLD in clinical settings.
Source: ConclusionsAuthors’ abstract
Aims
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature for nonalcoholic fatty liver. Along with obesity, fatty liver associated with metabolic dysfunction is increasing and has become a serious socioeconomic problem. Non-invasive testing for the confirmation of MAFLD, including the fatty liver index (FLI), can be used as an alternative method for diagnosing steatosis when imaging modalities are not available. To date, few studies have examined the effectiveness and validity of FLI for diagnosing MAFLD. Therefore, this study analyzed the effectiveness and validity of FLI for diagnosing MAFLD.
Methods
Medical records of men and women aged ≥ 19 years who underwent abdominal computed tomography (CT) examination at our facility between March 2012 and October 2019 were retrospectively reviewed. A comparative analysis between non-continuous variables was performed using the chi-squared test. The area under receiver operating characteristic (AUROC) curve was used to verify the effectiveness of FLI as a predictive index for MAFLD.
Results
Analysis of the association between MAFLD and abdominal CT revealed that the sensitivity and specificity of FLI for diagnosing MAFLD were 0.712 and 0.713, respectively. The AUROC of FLI for predicting MAFLD was 0.776.
Conclusions
Our study verified the accuracy of FLI for predicting MAFLD using CT. The FLI can be used as a simple and cost-effective tool for screening MAFLD in clinical settings.
Publication and source details
Original title: Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
A Lum Han
Diabetology & Metabolic Syndrome · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Korean Society for the Study of Obesity.KSSO202104Han A LumRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T09:49:02.937763+00:00
DOI: 10.1186/s13098-022-00811-2 · PMC8939216